By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Recombinant human erythropoietins > Epoetin beta and methoxy polyethylene glycol > Epoetin Beta-Methoxy Polyethylene Glycol Dosage
Recombinant human erythropoietins
https://themeditary.com/dosage-information/epoetin-beta-methoxy-polyethylene-glycol-dosage-11179.html

Epoetin Beta-Methoxy Polyethylene Glycol Dosage

Drug Detail:Epoetin beta and methoxy polyethylene glycol (Epoetin beta and methoxy polyethylene glycol [ e-poe-e-tin-bay-ta-meth-ox-ee-pol-ee-eth-il-een-glye-kol ])

Drug Class: Recombinant human erythropoietins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Anemia Associated with Chronic Renal Failure

Patients NOT on Dialysis:

Not currently on erythropoiesis-stimulating agents (ESAs):
Initial dose: 0.6 mcg/kg, intravenously (IV) or subcutaneously (SC), once every 2 weeks
Maintenance dose (when hemoglobin is stabilized): Administer once monthly, using twice the every 2 week dose; titrate as needed

Conversion From Epoetin alfa (EA):
EA dose under 8000 units/week: 60 mcg every 2 weeks OR 120 mcg monthly

EA dose 8000 to 16,000 units/week: 100 mcg every 2 weeks OR 200 mcg monthly

EA dose over 16,000 units/week: 180 mcg every 2 weeks OR 360 mcg monthly

Conversion From Darbepoetin alfa:
Darbepoetin alfa dose under 40 mcg/week: 60 mcg every 2 weeks OR 120 mcg monthly

Darbepoetin alfa dose 40 to 80 mcg /week: 100 mcg every 2 weeks OR 200 mcg monthly

Darbepoetin alfa dose over 80 mcg /week: 180 mcg every 2 weeks OR 360 mcg monthly

Comments:

  • Use is neither indicated or recommended for anemia from cancer chemotherapy.
  • Use is neither indicated or recommended as a substitute for red blood cell (RBC) transfusions when immediate correction of anemia is required.
  • Improvements in symptoms, physical function, or health related quality of life have not been shown.
  • Initiate therapy when hemoglobin is under 10 g/dL, the rate of hemoglobin decline is likely to require a RBC infusion, and reducing RBC transfusion related risks, including alloimmunization, is a goal.
  • If hemoglobin exceeds 10 g/dL, reduce or interrupt dose.
  • Use the lowest dose necessary to reduce the need for red blood cell transfusions.


Use: Anemia due to chronic kidney disease

Renal Dose Adjustments

See Usual Adult Dosing

Liver Dose Adjustments

Data not available

Dose Adjustments

General:

  • Do not increase the dose more often than every 4 weeks.
  • Dose reductions can be more frequent.
  • Avoid frequent dose changes.

Rapid Hemoglobin Rise (over 1 g/dL in any 14-day period): Reduce dose by 25% or more as necessary to reduce rapid responses.

Inadequate Response (hemoglobin increased 1 g/dL or less after 4 weeks of therapy): Increase dose by 25%
  • Patients without adequate response despite a 12-week dose escalation are unlikely to respond to more dose increases, but are at greater risk of adverse events.
  • Use the lowest dose necessary to reduce the need for red blood cell transfusions.

Hemoglobin Exceeds 10 g/dL: Reduce or interrupt dosing; use the lowest dose necessary to reduce the need for red blood cell transfusions.

Geriatrics: Clinical studies did not include enough patients over 65 years to determine if they react differently than younger patients.
  • Dose selection should be cautious, usually starting on the lower end of the dosing range, reflecting the increased likelihood of hepatic, renal, or cardiac dysfunction as well as other conditions and concomitant medications.

Precautions

US BOXED WARNING(S):
Chronic Kidney Disease:

  • In controlled trials, patients given erythropoiesis-stimulating agents (ESAs) had greater risks of death, serious adverse cardiovascular reactions, and stroke, when a hemoglobin level of 11 g/dL or higher was targeted.
  • No target hemoglobin level, ESA dose, or dosing strategy has been found that doesn't increase the risk.
  • Use the lowest dose necessary to reduce the need for red blood cell transfusions.

Cancer:
  • Use is neither indicated or recommended for anemia due to cancer chemotherapy.
  • A dose-ranging study terminated early due to increased deaths in patients on this drug versus another ESA.
  • ESAs shortened overall survival, and increased the tumor progression or recurrence risk in breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.

CONTRAINDICATIONS:
  • Uncontrolled hypertension
  • Pure red cell aplasia (PRCA) that begins after treatment with this or another ESA
  • Serious allergic reactions to this product (e.g. anaphylaxis, angioedema, bronchospasm, skin rash, urticaria)

Safety and efficacy have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Adult Dialysis patients:
Not currently on erythropoiesis-stimulating agents (ESAs):
Initial dose: 0.6 mcg/kg, intravenously (IV) or subcutaneously (SC), once every 2 weeks
Maintenance dose (when hemoglobin is stabilized): Administer once monthly, using twice the every 2 week dose; titrate as needed

  • Initiate therapy when hemoglobin is under 10 g/dL.
  • If hemoglobin nears or exceeds 11 g/dL, reduce or interrupt dose.
  • IV administration is preferred for dialysis patients, as immunogenicity may be less.


Pediatric Hemodialysis (5 to 17 years); for patients with hemoglobin stabilized on another ESA transferring to this drug:
Dose based on previous ESA dose that stabilized hemoglobin.

Transferring from epoetin alfa: 4 times the previous epoetin alfa dose/125, IV every 4 weeks (e.g. 4 x 1500 Units epoetin alfa per week/125 = 48 mcg epoetin beta-methoxy polyethylene glycol)

Transferring from darbepoetin alfa: 4 times the previous darbepoetin alfa dose/0.55, IV every 4 weeks (e.g. 4 x 20 Units darbepoetin alfa per week/0.55 = 145.5 mcg epoetin beta-methoxy polyethylene glycol every 4 weeks)

Peritoneal dialysis:
  • Safety and efficacy of have not been established in pediatric patients on peritoneal dialysis.

Other Comments

Administration advice:

  • May be administered subcutaneously (SC) or intravenously(IV) in adults.
  • IV is preferred for dialysis patients, as immunogenicity may be less.
  • IV is the only approved route in pediatric patients.
  • Safety and efficacy of SC administration have not been established in pediatric patients.

Storage requirements:
  • Refrigerate; keep in original carton to protect from light
  • May be kept at room temperature in the original carton for up to 30 days by the end user; discard after 30 days
  • Avoid vigorous shaking

IV compatibility:
  • Do not mix with parenteral solutions.

Monitoring:
  • Monitor hemoglobin at least weekly until stable when initiating or adjusting therapy.
  • Monitor hemoglobin at least monthly once stable.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by